Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.

ABSTRACT: There is now an increasing trend for targeting cancers to go beyond early diagnosis and actually improve Progression-Free Survival and Overall Survival. Identifying patients who might benefit from a particular targeted treatment is the main focus for Precision Medicine. Radiolabeled ligands can be used as predictive biomarkers which can confirm target expression by cancers using positron emission tomography (PET). The same ligand can subsequently be labeled with a therapeutic radionuclide for targeted radionuclide therapy. This combined approach is termed "Theranostics". The prostate-specific membrane antigen (PSMA) has emerged as an attractive diagnostic and therapeutic target for small molecule ligands in prostate cancer. It can be labeled with either positron emitters for PET-based imag

SUBMITTER: Kaewput C 

PROVIDER: S-EPMC9144463 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature